Evidence map›Paper›PMID 35408841›Full record

ReviewInternational journal of molecular sciences2022

The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer.

Nicole E Pellegrino, Arcan Guven, Kayleigh Gray, Punit Shah, Gargi Kasture, Maria-Dorothea Nastke, Anjan Thakurta, Stephane Gesta, Vivek K Vishnudas, Niven R Narain and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Article
  3. The role of HMGA1 in genome stability: Implications in human cancer.Cellular and molecular life sciences : CMLS · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nicole E PellegrinoBERG, 500 Old Connecticut Path, Framingham, MA 01701, USA.
Arcan GuvenBERG, 500 Old Connecticut Path, Framingham, MA 01701, USA.ORCID 0000-0002-3407-3609
Kayleigh GrayBERG, 500 Old Connecticut Path, Framingham, MA 01701, USA.
Punit ShahBERG, 500 Old Connecticut Path, Framingham, MA 01701, USA.
Gargi KastureBERG, 500 Old Connecticut Path, Framingham, MA 01701, USA.
Maria-Dorothea NastkeBERG, 500 Old Connecticut Path, Framingham, MA 01701, USA.
Anjan ThakurtaOxford Centre for Translational Myeloma Research, University of Oxford, Oxford OX3 7LD, UK.
Stephane GestaBERG, 500 Old Connecticut Path, Framingham, MA 01701, USA.
Vivek K VishnudasBERG, 500 Old Connecticut Path, Framingham, MA 01701, USA.
Niven R NarainBERG, 500 Old Connecticut Path, Framingham, MA 01701, USA.
Michael A KiebishBERG, 500 Old Connecticut Path, Framingham, MA 01701, USA.
University of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-translational modifications of proteins ensure optimized cellular processes, including proteostasis, regulated signaling, cell survival, and stress adaptation to maintain a balanced homeostatic state. Abnormal post-translational modifications are associated with cellular dysfunction and the occurrence of life-threatening diseases, such as cancer and neurodegenerative diseases. Therefore, some of the frequently seen protein modifications have been used as disease markers, while others are targeted for developing specific therapies. The ubiquitin and ubiquitin-like post-translational modifiers, namely, small ubiquitin-like modifier (SUMO) and neuronal precursor cell-expressed developmentally down-regulated protein 8 (NEDD8), share several features, such as protein structures, enzymatic cascades mediating the conjugation process, and targeted amino acid residues. Alterations in the regulatory mechanisms lead to aberrations in biological processes during tumorigenesis, including the regulation of tumor metabolism, immunological modulation of the tumor microenvironment, and cancer stem cell stemness, besides many more. Novel insights into ubiquitin and ubiquitin-like pathways involved in cancer biology reveal a potential interplay between ubiquitination, SUMOylation, and NEDDylation. This review outlines the current understandings of the regulatory mechanisms and assay capabilities of ubiquitination, SUMOylation, and NEDDylation. It will further highlight the role of ubiquitination, SUMOylation, and NEDDylation in tumorigenesis.

Indexed as

NeoplasmsSumoylationCarcinogenesisHumansProtein Processing, Post-TranslationalProteinsTumor MicroenvironmentUbiquitinUbiquitinationProteinsUbiquitincancerNEDDylationpost-translational modificationsSUMOylationubiquitination

Identifiers

PMID35408841
PMCPMC8999128
OpenAlexW4223494118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.